Terns Pharmaceuticals Acquired by Merck | Healthcare M&A Deal

Merck has completed the acquisition of Terns Pharmaceuticals, a pharmaceuticals business in the United States, for $5.8 billion. Merck acquires Terns Pharmaceuticals to add TERN-701, a novel oral allosteric BCR::ABL1 tyrosine kinase inhibitor, to its oncology pipeline for chronic myeloid leukemia. Terns Pharmaceuticals is focused on developing targeted therapies for Philadelphia chromosome-positive CML, including a Breakthrough Therapy Designation for adults previously treated with two or more tyrosine kinase inhibitors. The healthcare M&A merger acquisition is a public company acquisition by Merck, with Terns becoming a wholly-owned subsidiary and its Nasdaq Global Select Market listing delisted after a cash tender offer at $53.00 per share. Merck acquisitions of Terns Pharmaceuticals are expected to drive research and development expense and impact 2026 GAAP and non-GAAP EPS by about $0.12 per share.